Metraipolis › archive › dc_8a30508db15a

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database — Europe PMC PMID:41788805

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41788805
DOI
10.3389/fphar.2026.1765114
License (as archived)
solo-consultazione
Archived
2026-11-05T15:59:17.269Z
SHA-256 of the archived text
b13b7d15f3b1035aaaaef114f65f42506339b6c9ff8165100e69ba55b703ad3f
Stable URL of this page
https://metraipolis.com/documento/dc_8a30508db15a

How to cite

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database — Europe PMC PMID:41788805 — Europe PMC (en), https://europepmc.org/article/MED/41788805 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a30508db15a (Metraipolis archive dc_8a30508db15a, sha256 b13b7d15f3b1035aaaaef114f65f42506339b6c9ff8165100e69ba55b703ad3f)
BibTeX
@misc{dc8a30508db15a,
  title = {Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database — Europe PMC PMID:41788805},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41788805},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a30508db15a; sha256 b13b7d15f3b1035aaaaef114f65f42506339b6c9ff8165100e69ba55b703ad3f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41788805. Agents can read the archived copy with the MCP tool read_document.